{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-046109","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.756459+00:00","generated_at":"2026-05-22T03:19:25.498253+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CVRx Q1 revenue $12.3M (+15% YoY); net loss narrows; guides FY2025 rev $55-58M","bullets":["Total revenue $12.3M (+15% YoY); U.S. HF revenue $11.1M (+14%) on 353 implants.","Net loss $13.8M ($0.53/share) vs $22.2M ($1.04) in Q1 2024; cash $102.7M.","FY2025 revenue guidance $55-58M; Q2 revenue expected $13-14M.","Active U.S. implanting centers 227 (+19% YoY); gross margin 84%.","Real-world evidence: 85% reduction in HF hospital visits (Premier Healthcare Database)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-046109","json":"https://secwatch.observer/filing/0001104659-25-046109.json","markdown":"https://secwatch.observer/filing/0001104659-25-046109.md","text":"https://secwatch.observer/filing/0001104659-25-046109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465925046109/0001104659-25-046109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465925046109/tm2514410d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T03:19:25.498253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}